Gadoxetic_acid

Gadoxetic acid

Gadoxetic acid

Complex of gadolinium by a chelating agent derived from DTPA


Gadoxetic acid is a gadolinium-based MRI contrast agent.[3] Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals.[1][4]

Quick Facts Clinical data, Trade names ...

Medical uses

It is used to increase the T1 signal intensity while imaging the liver lesions such as benign cysts, hemangioma, and liver cancer. It is excreted into bile by active secretion.[5]

Pharmacokinetics

In those with end-stage renal failure, the clearance rate is only 17% with terminal half-life of 12 times longer than those with normal renal function.[5]


References

  1. "Eovist- gadoxetate disodium injection, solution". DailyMed. National Library of Medicine, National Institutes of Health, U.S. Health & Human Services. Retrieved 21 April 2021.
  2. "Active substance(s): gadoxetic acid disodium" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 14 January 2021.
  3. Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. (August 2021). "Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging". European Radiology. 31 (8): 5615–5628. doi:10.1007/s00330-020-07637-4. PMC 8270799. PMID 33523304.
  4. "Eovist - Homepage". Archived from the original on 2009-04-25. Retrieved 2009-03-22.
  5. "Clinical pharmacology and biopharmaceutics review" (PDF). Center for drug evaluation and research. Archived from the original (PDF) on 12 May 2021. Retrieved 15 December 2022.



Share this article:

This article uses material from the Wikipedia article Gadoxetic_acid, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.